Cel Sci (CVM) Cash & Current Investments (2010 - 2026)
Cel Sci (CVM) posted Cash & Current Investments of $1.9 million for Q1 2026, down 69.79% sequentially from $6.3 million in Q4 2025, and down 1.72% YoY from $1.9 million in Q1 2025.
Cel Sci (CVM) Cash & Current Investments (2010 - 2026) Analysis & Trends
Cel Sci has reported Cash & Current Investments for 17 years, with the latest figure at $1.9 million in Q1 2026.
- Quarterly Cash & Current Investments fell 1.72% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 1.72% YoY) and the FY2025 annual result came in at $11.0 million, up 131.15% from the prior year.
- Cash & Current Investments slipped to $1.9 million in Q1 2026 per CVM's latest filing, from $6.3 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $34.3 million in Q1 2022 and troughed at $435781.0 in Q2 2024.
- A 5-year average of $9.6 million and a median of $5.1 million in 2023 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2024 and 2025: Cash & Current Investments plunged 91.51% in 2024, then surged 313.13% in 2025.
- Over 5 years, Cash & Current Investments stood at $18.0 million in 2022, then slumped by 81.92% to $3.3 million in 2023, then jumped by 41.87% to $4.6 million in 2024, then soared by 35.98% to $6.3 million in 2025, then slumped by 69.79% to $1.9 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $1.9 million, $6.3 million, and $11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 6.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | 6.28 Mn |
| Sep 30, 2025 | 10.96 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 4.62 Mn |
| Sep 30, 2024 | 4.74 Mn |
| Jun 30, 2024 | 435,781.00 |
| Mar 31, 2024 | 5.33 Mn |
| Dec 31, 2023 | 3.26 Mn |
| Sep 30, 2023 | 4.15 Mn |
| Jun 30, 2023 | 5.14 Mn |
| Mar 31, 2023 | 10.05 Mn |
| Dec 31, 2022 | 18.02 Mn |
| Sep 30, 2022 | 22.67 Mn |
| Jun 30, 2022 | 28.07 Mn |
| Mar 31, 2022 | 34.28 Mn |
| Dec 31, 2021 | 37.11 Mn |
| Sep 30, 2021 | 42.21 Mn |
| Jun 30, 2021 | 47.11 Mn |